A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease
Status:
Recruiting
Trial end date:
2049-12-01
Target enrollment:
Participant gender:
Summary
ORION-4 is a research study coordinated by the University of Oxford and co-sponsored by The
University of Oxford and Novartis (Protocol: CTSU_MDCO-PCS-17-01 (CKJX839B12301)). The study
aims to find out if a new cholesterol-lowering injection (inclisiran) safely lowers the risk
of heart attacks and strokes in people who have already had one of these conditions, or who
have had an operation or procedure to treat blocked arteries.
Phase:
Phase 3
Details
Lead Sponsor:
University of Oxford
Collaborators:
Novartis Pharmaceuticals The Medicines Company The TIMI Study Group